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Background. In-stent restenosis (ISR) is the gradual narrowing of the vessel lumen after coronary stent implantation due to the
increase in vascular smooth muscle cell proliferation. Vascular endothelial growth factor (VEGF) protein plays an important role
in this process. Our aim was to analyze the association of single nucleotide polymorphisms of the VEGF gene (rs2010963 and
rs6999447) with the occurrence of ISR after coronary artery bare metal stent (BMS) implantation. Methods. 205 patients with a
history of BMS implantation and a repeated coronarographywere prospectively enrolled. Patients were assigned to diffuse restenosis
group (𝑛 = 105) and control group (𝑛 = 100) and VEGF genotypes were determined. Results. Diffuse ISR was significantly
more frequently observed in patients with homozygous normal genotype of rs2010963 polymorphism, and this polymorphism was
independently associated with diffuse ISR. Conclusions. RS2010963 is associated with higher incidence of development of diffuse
coronary ISR in patients treated with BMS implantation.
1. Introduction
In the era of balloon angioplasty without stent implantation
in-stent restenosis (ISR) occurred in 40–50% [1]. Coronary
stents were developed to lower the rate of early restenosis.
However, ISR still occurs in 10–30% of the interventions
with deployment of bare metal stents (BMS) and therefore
still forms a clinically important problem [2]. Although
new generation drug eluting stents (DES) further reduced
ISR rate and need for repeat revascularization, BMS are
still widely used. Moreover, recently Bønaa et al. found no
significant difference between receivers of BMS and DES in
the composite outcome of death from any cause or nonfatal
spontaneous myocardial infarction [3].
After coronary stent implantation mechanical injuries of
vessel wall result in vascular smooth muscle cell (VSMC)
activation and proliferation and a phenotype change from
contractile to proliferative and secretory phenotype [4, 5].
Histological analyses have revealed that vascular smooth
muscle cells (VSMCs) represent the majority of neointima
cells [6]. The neointima proliferation leads to narrowing of
the coronary lumen [7].
Risk for restenosis is particularly high among patients
with diabetes mellitus; this may be associated with metabolic
alterations that promote endothelial dysfunction, accelerate
intimal hyperplasia, and increase platelet aggregability and
thrombogenicity [8]. There is evidence that gender itself
(female) predisposes to restenosis [9] and some patients may
have genetically higher risk [10, 11]. Genetic polymorphisms
associated with high risk for restenosis include polymor-
phisms in genes coding for angiotensin II receptor type 1 [12],
CD18 [13], interleukin-1 receptor antagonist [14], glycopro-
tein receptor IIIa [15], and mannose-binding lectin [16].
On invasive coronarography in-stent restenosis can
be classified according to Mehran’s classification to focal
(Mehran I) and diffuse (Mehran II–IV) groups [17]. Former
type is determined by local and procedural factors, while the
latter shows significant relation with general, patient-related
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factors [18] such as diabetes or growth factors. Numerous
studies of restenosis have indicated that transforming growth
factor beta 1 (TGF-𝛽1), platelet-derived growth factor beta
(PDGFB), epidermal growth factor (EGF) [19], basic fibrob-
last growth factor (bFGF), and vascular endothelial growth
factor (VEGF) play an important role in VSMC proliferation
and migration to the tunica intima [20]. The rs699947 and
rs2010963 polymorphisms are located in the 5󸀠UTR region
of the VEGF gene affecting the transcription and expression
of the protein. The rs699947 polymorphism of the VEGF
gene is associated with a higher risk of developing certain
neoplastic diseases [21] andwith the development of coronary
collaterals in patients with coronary artery disease [22] or
with susceptibility to coronary heart disease [23].
According to these findings the involvement of the VEGF
in pathological processes leading to restenosis is known, but
only one study has investigated the role of rs699947 gene
polymorphisms in relation to restenosis [24], whereas the
roles of functional polymorphism rs2010963 in restenosis
have not yet been studied. The aim of this study was to
analyze the association of VEGF’s polymorphisms and the
development of coronary in-stent restenosis after bare metal
stent implantation.
2. Methods
2.1. Subjects, Interventions. 205 patients with a history of
percutaneous coronary intervention (PCI) and BMS implan-
tation, who presented with nonacute or acute cardiac symp-
toms which warranted a repeat coronary angiogram, were
prospectively enrolled between 2011 and 2013 in the Heart
and Vascular Center, Semmelweis University. All patients
received standard therapy according to the actual guidelines.
ISR has been evaluated by experienced clinicians according
to Mehran’s classification and patients have been categorized
to the diffuse restenosis group and control group (without
diffuse restenosis).
2.2. Biological Samples and Genotyping. Genomic DNA was
extracted from whole peripheral blood with a protease
based technique (Flexigene DNA System, Qiagen, Hilden,
Germany). Samples (1mL) were added to a lysis buffer and
were thoroughly mixed and centrifuged. After discarding
the supernatant, samples were denaturized, and DNA was
ethanol precipitated and reconstituted in the provided buffer.
Samples were stored at −80∘C. Estimation of the DNA yield
and quality control was done by spectrophotometry and
determination of the 260/280 absorption ratio (Nanodrop-
2000,Thermo Scientific, Wilmington, USA), and the average
yield was 96.0 𝜇g (range 25–370 𝜇g).
Determination of the alleles of the VEGF gene C−2578A
(rs699947) was performed with quantitative real-time PCR
(RT-qPCR) (StepOnePlus, AppliedBiosystems). Predesigned
primers were provided by Applied Biosystems (kit number:
c___8311602_10). Reactions were performed according to the
manufacturer’s protocol and for each run parallel samples
with positive controls were used.
Genotyping of G+405C (rs2010963) was performed by
RT-qPCR and melting curve analysis using LightCycler
(Roche GmbH, Penzberg, Germany). The following primers
were used: 5󸀠-CCAGAAACCTGAAATGAAGG-3󸀠 in the for-
ward direction and 5󸀠-GGGCTCGGTGATTTAGC-3󸀠 in the
reverse direction, the probe sequences were 5󸀠-LC640-TGG
AATTGGATTCGCCATTTTATTTTTCTTgC-3󸀠 and 5󸀠-
GACCCAGCACGGTCCCTC-FL.ThePCRmix contained
1 𝜇L of the genomic DNA, 5 𝜇M of primers and probes, 1𝜇L
of LightCycler FastStart DNA Master HybProbe kit (Roche),
and 2.5mM MgCl2. The initial 10min denaturation at 95∘C
was followed by 35 cycles, denaturation (95∘C; 10 s), annealing
(52–56–60∘C; 15 s), and extension (72∘C; 10 s), on LightCycler.
Melting curve analysis was performed following the PCR and
the Tm of the products was determined. The melting points
(Tm) were 59∘C for C and 67∘C for G alleles.
All assays were performed in 96-well arrays, and each
plate contained controls. Genotyping of 10% of the samples
was performed for quality control, with complete congru-
ence. Genetic analysis was performed blinded to patient data,
with the provided software. We established the genotypes
for all patients. The genotype frequencies of two SNPs were
all in agreement with the Hardy–Weinberg equilibrium test
(𝑝 > 0.05).
2.3. Statistical Analyses. Data were collected in Microsoft
Excel 2003 and were analyzed with SPSS 13.0 for Windows
(SPSS, Chicago, USA) software. Data are presented as mean
± SD for continuous variables, or 𝑛 (%) for categorical
variables. Comparisons between two groups were performed
using Student’s t-test for continuous variables, whereas for
continuous nonparametric variables Mann–Whitney U tests
were performed. Categorical values were compared by using
the chi-square test. Multivariate logistic regression has been
performed with adjustment for clinical variables that reached
a 𝑝 value of <0.3 when comparing patients with and without
significant diffuse ISR. The genotype frequency was tested
for deviation from Hardy–Weinberg equilibrium by using
Pearson’s chi-square test. All analyses were performed two-
tailed, and 𝑝 < 0.05 was considered as significant.
3. Results
3.1. Patient Characteristics. The total number of 205 patients
was involved in our study and categorized into diffuse
restenosis and control group. The diffuse restenosis group
(𝑛 = 105) included patients with significant diffuse ISR
(Mehran II–IV) at recoronarography (73.3% men). Control
group (𝑛 = 100) included patients with no or only focal
restenosis (Mehran I) at recoronarography in the target bare
metal stent (74.0% men).
Clinical baseline characteristics of the 205 patients are
described in Table 1.Themean age (control: 66.5 (±10.2) years
versus restenosis: 65.7± 9.8 years;𝑝 = 0.601) and distribution
of genders (control: 74% male versus restenosis: 73.3% male;
𝑝 = 0.914) did not differ significantly. About one-third
of patients had diabetes mellitus (71 patients, 35%), mostly
type 2. Most patients had hypertension and hyperlipidaemia;
only 5.3% were not treated for hypertension and 9.1% were
not on lipid-lowering therapy and had normal lipid levels.
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Table 1: Patient characteristics. Continuous variables are presented as mean (±SD). Dichotomous variables are presented as number of
patients (percentage).
Variable Control group (𝑛 = 100) Restenosis group (𝑛 = 105) 𝑝 value
Age, years 66.5 (±10.2) 65.7 (±9.8) 0.601
Gender, male 74 (74%) 77 (73.3%) 0.914
Antihypertensive therapy 96 (97.0%) 98 (93.3%) 0.229
Lipid-lowering therapy 90 (91.8%) 95 (90.5%) 0.733
Diabetes mellitus 34 (35.1%) 37 (36.6%) 0.816
Obesity, BMI > 25 79 (82.3%) 77 (74.8%) 0.197
BMI 28.0 (±3.8) 28.1 (±4.4) 0.817
Smoking 13 (13.0%) 8 (7.6%) 0.204
Peripheral vascular disease 13 (13%) 18 (17.1%) 0.396
Chronic renal failure 7 (7%) 3 (2.9%) 0.123
Maximal CKMB level 114.8 (±102.3) 95.3 (±140.3) 0.322
Acute coronary disease 56 (56.6%) 62 (59.0%) 0.720
Angina pectoris 40 (40%) 37 (35.2%) 0.482
Cardiogenic shock (Killip IV) 2 (2%) 4 (3.8%) 0.527
Multi-branch stented 8 (8.0%) 14 (13.3%) 0.004
Total number of stents 1.42 (±0.75) 1.65 (±0.97) 0.056
Total stent length in mm 30.7 (20.7) 38.9 (25.5) 0.119
Stent diameter in mm 3.1 (0.4) 3.2 (2.6) 0.614
Ejection fraction 52.5 (11.2) 52.8 (10) 0.864
Average time to repeated angiogram (years) 2.65 (±2.72) 1.12 (±1.43) <0.001
Obesity (bodymass index (BMI)> 25)was present in 76.1% of
patients. 21 (10.2%) cases had history of stroke or TIA and 31
(15.1%) cases had peripheral artery disease in the anamnesis;
22 (10.5%) of the patients were current smokers at the time
of the second angiography. 10 patients had chronic renal
failure and 6 patients had cardiogenic shock. The presence
of all above listed factors except chronic renal failure did
not differ significantly in the groups. The average time to
repeated angiogram was 2.6 ± 2.7 years in the control group
and 1.1 ± 1.4 years in the restenosis group (𝑝 < 0.001).
According to this, in-stent restenosis occurred and caused
symptoms earlier while controls had a longer asymptomatic
period before recoronarography was performed.
3.2. Interventions. There was no significant difference in the
indication of stent implantation between the two groups:
acute coronary disease in 56.6% of the control group and
59.0% in the restenosis group. Total number of deployed
stents was not significantly higher in restenosis group: 1.42
(0.75) versus 1.65 (0.97) (𝑝 = 0.056). Total stent length and
stent diameter were not significantly different between the
two groups (Table 1). One-tenth of the patients had multiple
branches stented for the first intervention, 8 (8%) in the con-
trol group and 14 (13.3%) in the restenosis group (𝑝 = 0.004).
3.3. Genetic Analysis Results. Allele frequencies were
similar between genders (rs2010963: 50.1%/41.7%/9.3% in
men and 40.7%/50%/9.3% in women, (G/G, G/C, C/C)
𝑝 = 0.454; rs699947: 25.5%/48.3%/26.2% in men and
15.4%/48.1%/36.5% in women, (A/A, A/C, C/C) 𝑝 = 0.209).
The genotype distribution conformed to Hardy–Weinberg
equilibrium (𝑝 = 0.45 and 𝑝 = 0.65, resp.). Genotype dis-
tributions for the groups of patient with no restenosis, focal
restenosis, and diffuse restenosis are shown in Table 2. There
was no statistically significant difference among these groups.
For further analysis, we merged the focal restenosis group
with the no-restenosis group as the focal in-stent restenosis
is suspected to have different underlying pathomechanism
compared to diffuse in-stent restenosis. Comparison of the
genotype distribution of this control group to the diffuse in-
stent restenosis group showed that diffuse in-stent restenosis
was significantly less frequent in C/G and C/C genotypes
(variant carrier) of rs2010963 polymorphism versus individ-
uals with the G/G (homozygous normal) genotype (OR 0.56,
𝑝 = 0.04). Restenosis frequency did not differ between the
two groups for rs699947 polymorphism (Table 3).
3.4. Multivariate Analysis. Multivariate analysis adjusted for
clinical variables (BMI, hypertension, smoking, chronic renal
failure, average time to repeated angiogram, multiple branch
stent deployment, total stent length, and total number of
implanted stents) revealed that the homozygous normal
(A/A) genotype of rs2010963 is related to higher risk of diffuse
ISR. The rs699947 polymorphisms of VEGF gene are not
associated with a risk of diffuse ISR (Table 4).
4. Discussion
In our nonrandomized prospective study, we found a signif-
icant association of rs2010963 VEGF polymorphism and the
development of diffuse in-stent restenosis after coronaryBMS
implantation. This association was independent of certain
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Table 2: Genotype distribution of no-restenosis group and focal and diffuse restenosis groups; G/G versus G/C + C/C and A/A versus A/C
+ C/C, chi-square.
Polymorphism Genotype No-restenosis group 𝑛 (%) Focal restenosis group (%) Diffuse restenosis group 𝑛 (%) 𝑝
rs2010963 Normal (G/G carriers) 28 (40%) 13 (43.3%) 58 (55.2%) 0.119
Variant (G/C + C/C carriers) 42 (60%) 17 (56.7%) 47 (44.8%)
rs699947 Normal (A/A carriers) 13 (18.6%) 8 (26.7) 28 (26.7%) 0.436
Variant (A/C + C/C carriers) 57 (81.4%) 22 (73.3%) 77 (73.3%)
Table 3: Genotype distribution of control group (no-restenosis + focal restenosis) versus diffuse restenosis group; G/G versus G/C + C/C
and A/A versus A/C + C/C, chi-square.
Polymorphism Genotype Control group 𝑛 (%) Diffuse restenosis group 𝑛 (%) 𝑝
rs2010963 Normal (G/G carriers) 41 (41%) 58 (55.2%) 0.041
Variant (G/C + C/C carriers) 59 (59%) 47 (44.8%)
rs699947 Normal (A/A carriers) 21 (21%) 28 (26.7%) 0.342
Variant (A/C + C/C carriers) 79 (79%) 77 (73.7%)
Table 4: Results of the multivariate logistic regression analyses with adjustment for risk factors and VEGF rs2010963 variant genotype (G/C
+ C/C) with in-stent restenosis as a dependent variable. Hosmer–Lemeshow test 𝑝 = 0.139.
Risk factor OR CI 𝑝
Lower Upper
Hypertension or antihypertensive therapy 0.45 0.043 4.692 0.503
BMI 1.05 0.906 1.235 0.478
Smoking 0.493 0.088 2.757 0.42
Chronic renal failure 0.754 0.034 16.807 0.859
Multi-branch stented 0.982 0.217 14.368 0.596
Total number of stents 1.441 0.421 4.939 0.561
Average time to repeated angiogram 0.226 0.756 0.413 0.004
Total stent length 1.002 0.958 1.049 0.992
VEGF rs2010963 0.754 0.034 0.535 0.003
clinical factors. VEGF is expressed by vascular endothelial
cells, as well as additional cell types [25]. Association has
been identified between VEGF polymorphisms and the risk
of coronary artery disease [26], the development of collat-
eral circulation in individuals with coronary artery disease
[22]. VEGF contributes to mediating neovascularization of
atherosclerosis plaques [27] and has been found to be asso-
ciated with intimal thickening and thrombus development
[28] and higherVEGF levels after PCI are related to restenosis
after DES implantation [29].
Following PCI, a process similar to wound healing takes
place in the affected coronary artery. VEGF has an important
role directly in the progress of that endothelialization process
and also it has an indirect effect on the inflammation cascade
andVSMCproliferation andmigration [30]. Accordingly, the
endothelial stimulating effect of VEGF is essential for restor-
ing the integrity of the vessel wall but it can also become the
cause of restenosis through neointima hyperplasia [31]. Slight
modifications of VEGF production or function due to gene
polymorphisms can have remarkable consequences. Both
rs699947 and rs2010963 are located in the promoter region
(5󸀠UTR) and known to influence the transcription of VEGF
gene resulting in a lower serum level of the protein [32].
Rs2010963 (+405C>G) is probably a functional polymor-
phism, as serum VEGF levels in subjects with GG genotype
have been found to be higher than in other genotypes [32].
Rs699947 has been previously associated with coronary
artery disease [23]. It is noteworthy that Osadnik et al. [24]
investigated the role of this polymorphism in development of
angiographically significant ISR, but, in their study, focal and
diffuse ISR was not distinguished. However, we compared
patients with diffuse ISR to patients with no or focal ISR
because diffuse ISR has different underlying mechanism
compared to focal one, as the former is related to general fac-
tors, such as genotype, and the latter is rather related to pro-
cedural factors. Although rs699947 has been previously asso-
ciated with coronary artery disease, our findings are in con-
cordance with Osadnik et al.’s [24] observation as we found
no significant association between diffuse ISR and rs699947.
Polymorphism rs2010963 was demonstrated to be asso-
ciated with several disorders, such as diabetic retinopa-
thy [33], diabetic nephropathy [34], metabolic syndrome
[35], myocardial infarction [36], and impaired prognosis in
patients with chronic heart failure [37]. VEGF rs2010963
SNPs have been associated with development of collateral
circulation [22] andCAD [38]. In contrast, no association has
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been observed with HELLP syndrome (Hemolysis Elevated
Liver enzymes Low Platelet count) according to Nagy et al.
[39], although rs699947 genotype carriers had an increased
risk of HELLP syndrome. Merlo et al. found significant
association between VEGF levels and rs2010963 polymor-
phism but observed no association with carotid intima-
media thickness [40]. Moreover, in a recent study [23] this
SNP was not found to be associated with coronary artery
disease. We found a significant association of rs2010963
VEGF polymorphism and the development of diffuse in-
stent restenosis in our study population. The association
remained present after adjusting for certain clinical factors
in multivariate analysis. Particularly, we found that the
association is independent of the presence of hypertension.
As an influence of the polymorphism on hypertension has
been described before [41], it is relevant that our observation
implies an effect of the polymorphism on ISR without regard
to hypertension. It is notable that only the rs2010963 showed
association with diffuse in-stent restenosis even if both SNPs
are known to affect the transcription and expression of
VEGF. The explanation for that could be due to the fact
that in a highly polymorphic gene such as VEGF no single
SNP is responsible for the VEGF production, but, rather,
the influence of multiple SNPs (i.e., haplotypes) is more
likely. Additional SNPs residing on the same haplotypes
(i.e., in linkage disequilibrium) could represent the causal or
functional variants. The genetic variations of the gene need
further study in order to refine the “at-risk” haplotype, which
can then be used in a larger prospective study of patients [42].
5. Conclusions
In our nonrandomized prospective study, we found a sig-
nificant association of rs2010963 VEGF polymorphism and
the development of diffuse in-stent restenosis after coronary
BMS implantation. This association was independent of
certain clinical factors. We found no significant association
between diffuse ISR and rs699947. Preventing restenosis is
an important issue of coronary interventions that should
start even before the procedure. Early recognition of the
diseases and quick reaction usually mean that we face a less
complicated lesion, therefore a lower restenosis rate. But there
are some factors associatedwith ISR that we cannot influence,
such as genetic polymorphisms. With the rapid development
of genotyping technologies, examination of several polymor-
phismsmay be accessible as routine diagnostics and therefore
personalized risk assessment could be performed enabling
better selection of patients for primary DES or bioabsorbable
stent implantation.
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